메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

Intelligent perimeter protection white paper: How multi-sensi…

HANGZHOU, China, Sept. 5, 2025 -- Perimeter protection is the essential first line of defense in physical security, acting as a critical barrier against unauthorized access and safeguarding valuable assets. However, traditional perimeter security systems often struggle with false alarms, environmental interference, and costly manual verification — issues that can undermine both safety and efficiency. As threats grow in sophistication and perimeter security needs become more dynamic, organizations require smarter, more adaptive solutions that can deliver accurate detection and real-time respon
- 김갑성 기자
- 2025-09-05 10:53
Medidata Secures a Leader Position in Everest Group's PEAK…

Medidata eCOA was the highest Leader recognized in the evaluation, supporting over 1M+ patients and reducing study build timeline by up to 50% compared to the industry standard SINGAPORE, Sept. 5, 2025 -- Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, has been recognized as a Leader in Everest Group's Life Sciences Electronic Clinical Outcome Assessment (eCOA) Products PEAK Matrix® Assessment 2025. The report assessed 19 providers based on their demonstrated success in delivering products and drivin
- 김갑성 기자
- 2025-09-05 10:00
Smartee and Dental Monitoring Partner to Simplify Refinement Wo…

SHANGHAI, Sept. 5, 2025 -- Smartee Denti-Technology, a leading innovator in clear aligner solutions, and Dental Monitoring, the global leader in AI-powered remote monitoring for orthodontics, today announced a new integration designed to simplify and accelerate refinement workflows for orthodontists and dental professionals. Traditionally, refinement in clear aligner treatment requires patients to visit their orthodontist's office for an intraoral scan. The scan is then submitted to Smartee to generate a new treatment plan. While precise, this process often adds extra appointme
- 김갑성 기자
- 2025-09-05 09:30
Olympus Announces Distribution Partnership with MacroLux…

WESTBOROUGH, Mass., Sept. 4, 2025 -- Olympus Corp., a global medical technology company committed to making people's lives healthier, safer and more fulfilling, announced today an exclusive global distribution agreement with MacroLux Medical Technology Co., Ltd. to distribute single-use urology products. The agreement includes multiple single-use cystoscopes, ureteroscopes and suction access sheaths. These devices are used to access and visualize the bladder and urinary tract to diagnose and treat urinary diseases and disorders such as kidney stones. "We ar
- 김갑성 기자
- 2025-09-04 22:12
Alma, a Sisram Medical Company, Announces Strategic Colla…

HONG KONG, Sept. 4, 2025 -- Sisram Medical (1696.HK), a global leading innovator and provider of holistic medical aesthetic solutions, today announced a strategic collaboration between its subsidiary Alma, a global leader in energy-based medical and aesthetic solutions, and Jamie Sherrill ("Nurse Jamie"), the internationally recognized celebrity skin-care expert, entrepreneur, and media personality. The partnership marks an important step in Alma's strategy to expand consumer engagement and strengthen its leadership in premium aesthetic technologies. With more than two decade
- 김갑성 기자
- 2025-09-04 22:00
Accro Bioscience to Present Phase II Data of AC-201 for Plaqu…

NEW YORK and SUZHOU, China, Sept. 4, 2025 -- Accro Bioscience (Accropeutics), a clinical-stage biotech company focused on molecular mechanisms of regulated cell death and related pathogenesis in human diseases, today announced that it will present results from a Phase II clinical study evaluating AC-201, an oral, selective TYK2/JAK1 Inhibitor, in moderate-to-severe plaque psoriasis, at the European Academy of Dermatology & Venereology (EADV) Congress, being held September 17-20th, in Paris. Details of the presentation are as follows:Abstract Type: Oral Presentation in the Late Brea
- 김갑성 기자
- 2025-09-04 20:24
Halia Therapeutics to Participate in the Morgan Stanley 23rd A…

LEHI, Utah, Sept. 4, 2025 -- Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company developing first-in-class anti-inflammatory therapies, today announced that the Company plans to participate in the Morgan Stanley 23rd Annual Global Healthcare Conference. Jared Bearss, Chief Operating Officer of Halia, will provide a business overview presentation on Tuesday, September 9, 2025 at 7:00 am ET. About Halia Therapeutics Halia Therapeutics is a clinical-stage biopharmaceutical company focused on treating the root causes of inflammation. Leveraging geneti
- 김갑성 기자
- 2025-09-04 20:00
Angel Yeast Protein Receives U.S. GRAS Certification, Opening t…

SHANGHAI, Sept. 4, 2025 -- Angel Yeast (SH600298), a leading global provider of yeast and fermentation-based ingredients, announced today that its proprietary yeast protein, AngeoPro, has been granted Generally Recognized as Safe (GRAS) status by the U.S. Food and Drug Administration (FDA). The designation not only affirms the safety of the product but also marks a significant milestone in Angel Yeast's effort to expand the role of sustainable yeast protein in the global food supply. Positioned as a solution to challenges such as food security, climate change, and the
- 김갑성 기자
- 2025-09-04 20:00
Sentec Receives FDA Clearance for LuMon™ Electrical Imped…

The LuMon™ System is also CE-marked under EU MDR and registered with TGA in Australia. LINCOLN, R.I., Sept. 4, 2025 -- Sentec, a global leader in non-invasive patient monitoring, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its LuMon™ Electrical Impedance Tomography (EIT) system for premature infant, infant, adolescent, and adult patients—making it the first EIT technology in the United States available for premature infants and for spontaneously breathing patients. The LuMon™ EIT System delivers functional lu
- 김갑성 기자
- 2025-09-04 19:00
UNSW and NeuRA Lead New Study to Explore How ReNeuWell® A…

SYDNEY, Sept. 4, 2025 -- A clinical trial is being launched by researchers from UNSW and Neuroscience Research Australian (NeuRA) for a new app called ReNeuWell®, based on a scientifically validated measure of wellbeing. The application has been designed in collaboration with a research team led by A/Professor Justine Gatt from UNSW's School of Psychology and NeuRA. It uses the COMPAS-W Wellbeing Scale - which measures both subjective and psychological wellbeing, a scale developed by A/Prof Justine Gatt and that has been validated in neuroscience. Miroma Project Factory, sp
- 김갑성 기자
- 2025-09-04 06:23

이전

51 52 53 54 55 56 57 58 59 60

많이 본 기사

최근기사

2025-10-22_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 10월 22일 10시 40분